Enrasentan, formerly known as SB-217242, is a dual receptor endothelin antagonist with a higher affinity for ET(A) receptors. In an animal model of hypertension and cardiac hypertrophy the drug has reduced blood pressure, prevented cardiac hypertrophy and preserved myocardial function. Enrasentan improves survival, limits left ventricular remodeling, and preserves myocardial performance in hypertensive cardiac hypertrophy and dysfunction. References: Prasad SK, Dargie HJ, Smith GC, Barlow MM, Grothues F, Groenning BA, Cleland JG, Pennell DJ. Comparison of the dual receptor endothelin antagonist enrasentan with enalapril in asymptomatic left ventricular systolic dysfunction: a cardiovascular magnetic resonance study. Heart. 2006 Jun;92(6):798-803. Epub 2005 Dec 9. PubMed PMID: 16339819; PubMed Central PMCID: PMC1860639.

纯度：≥98%

CAS：167256-08-8